{
  "abstract": "Background and Importance Trans arterial chemoembolisation (TACE) is the standard treatment for intermediate-stage hepatocellular carcinoma (HCC), yet patient outcomes vary widely. The Hepatoma Arterial-embolisation Prognostic (HAP) score was developed to stratify prognosis based on baseline parameters, but its real-world predictive value remains uncertain.Aim and Objectives To evaluate the prognostic value of the HAP score in patients undergoing first-line TACE for HCC, and to explore its correlation with overall survival (OS) and progression-free survival (PFS) in a real-world setting.Material and Methods A retrospective study was conducted including patients diagnosed with HCC who underwent their first TACE between September/2023-September/2025. The HAP score was calculated based on baseline albumin, bilirubin, alpha-fetoprotein, and maximum tumour diameter. Patients were stratified into two groups (A+B and C+D, where A and B represent best prognosis). Survival outcomes were estimated using Kaplan–Meier analysis. Associations between HAP category and OS/PFS were assessed using log-rank tests and Cox proportional hazards models.Results Thirty-eight patients were included. The distribution of HAP categories was: A+B, 73.6% (N=28); C+D, 26.4% (N=10). Baseline characteristics are summarised in table 1.Abstract 4CPS-161 Table 1Baseline characteristics A+B C+D Male sex (%) 85.7 80 Median age (years, range) 74.5 (58–88) 73 (68–79) Median albumin (g/dL, range) 4 (2.9–7.1) 3.8 (2.8–3.5) Median total bilirubin (mg/dL, range) 0.91 (0.21–3.06) 1.4 (1.2–3.6) Median alpha-fetoprotein (ng/mL, range) 3.9 (<2–943.2) 3.6 (<2–181) Median tumour size (cm, range) 3.05 (1–7) 3 (1.3–5.2) Median PFS: 12.23 months (95% CI, 9.29–15.17) in group A+B and 6.53 months (95% CI, NR–NR) in C+D (HR 1.08, 95% CI 0.34–3.36; p = 0.895).Median OS: 22.83 months (95% CI, NR–NR) in group A+B and 24.07 months (95% CI, NR–NR) in C+D (HR 1.69, 95% CI 0.14–19.71; p = 0.667).Conclusion and Relevance In this real-world cohort, the HAP score did not show a significant correlation with OS or PFS in patients undergoing first TACE for HCC. Although patients with better HAP categories (A+B) had numerically longer PFS, the difference was not statistically significant, likely due to small sample size and limited heterogeneity baseline characteristics. Larger prospective studies are needed to clarify the prognostic utility of the HAP score in clinical practice.Conflict of Interest No conflict of interest",
  "authors": [
    {
      "affiliations": [
        "Hospital Universitario Puerto Real, Pharmacy, Puerto Real, Spain"
      ],
      "name": "Y Reyes-De-La-Mata"
    },
    {
      "affiliations": [
        "Hospital Universitario Puerto Real, Pharmacy, Puerto Real, Spain"
      ],
      "name": "E Pisarro-Baron"
    },
    {
      "affiliations": [
        "Hospital Universitario Puerto Real, Pharmacy, Puerto Real, Spain"
      ],
      "name": "P Frias-Ruiz"
    },
    {
      "affiliations": [
        "Hospital Universitario Puerto Real, Pharmacy, Puerto Real, Spain"
      ],
      "name": "C Martinez-Diaz"
    },
    {
      "affiliations": [
        "Hospital Universitario Puerto Real, Pharmacy, Puerto Real, Spain"
      ],
      "name": "MD Gil-Sierra"
    },
    {
      "affiliations": [
        "Hospital Universitario Puerto Real, Pharmacy, Puerto Real, Spain"
      ],
      "name": "V Vazquez-Vela"
    }
  ],
  "title": "4CPS-161 Prognostic value of first trans arterial chemoembolisation with hepatoma arterial-embolisation prognostic score in hepatocellular carcinoma: real-world data",
  "uid": "9071abb3-be13-50aa-ac3d-c8ac6c21206d"
}